Glenmark intros generic Vimpat
Generic Vimpat is used to treat seizures.
Glenmark is releasing lacosamide oral solution, 10 mg/ml, which is the generic of UCB’s Vimpat Oral Solution.
Vimpat Oral Solution, 10 mg/ml had a market value of approximately $57 million for the 12 months ending October 2024, per IQVIA data.
[Read more: Glenmark debuts Olopatadine Hydrochloride Ophthalmic Solution OTC]
Marc Kikuchi, president and business head, North America at Glenmark said, “We are excited to announce the launch of lacosamide oral solution, 10 mg/ml, strengthening our commitment to bring to market quality and affordable alternatives for patients.”
[Read more: Glenmark releases generic Travatan Z]